Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. The following report covers all immunology disorders, with a particular focus on four key areas: rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD) and transplant rejection/graft versus host disease (GVHD).

Immunology drugs market is projected to grow to $113 billion in 2023, at a compound annual growth rate (CAGR) of over 8%. The market size in the US is expected to increase at a CAGR of 6.58%, therefore accounting for approximately half of the global immunology market.

The prevalence populations of many indications within immunology are increasing, which is one of the major drivers of the expected market growth. For example, the prevalence population of RA across the seven major markets is expected to increase from 6.11 million in 2016 to 6.66 million in 2023.

Immunology market contains a number of blockbuster drugs, most of which are mAbs that target tumor necrosis alpha (TNF-α), a key pro-inflammatory cytokine. These include Humira (adalimumab), the most successful drug industry-wide, as well as Remicade (infliximab), Rituxan (rituximab), Simponi (golimumab) and Cimzia (certolizumab pegol). However, due to several recent and upcoming patent expiries, this drug class will suffer from biosimilar erosion over the forecast period, resulting in revenue decline and reduced dominance.

The first TNF biosimilars were approved several years ago when the first patents expired, but they are only now starting to have an impact on the revenue of their premium counterparts. For example, Remsima and Inflectra are Remicade biosimilars that have been approved in the EU, and Inflectra also has FDA approval to be marketed in 2018 when the patent for Remicade expires in the US. These biosimilars are exerting a very noticeable impact on Remicade’s revenue, which peaked in 2014 at $9.9 billion but is expected to fall to $3 billion by 2023.

Furthermore, there are also several drugs that have recently been approved - such as Cosentyx and Otezla - and several in late-stage pipeline development - such as, filgotinib, AR-101 and upadacitinib tartrate - that are expected to become blockbuster drugs over the forecast period, generating further market growth within immunology.

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.

Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.

Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.

Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.

Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.

Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.

Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.

Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.

Scope

The immunology market landscape is expected to change. Biosimilar competition is expected to affect the revenue of the big blockbuster drugs, and novel targets are expected to enter the market and drive market growth.

Overall, there are 2,070 immunology products in the pipeline.

Which molecular targets are most prominent within the pipeline?

How do the key indications differ in terms of molecule type?

How does the composition of the pipeline compare with that of the existing market?

What mechanisms of action are most common for pipeline drugs?

The market size for immunology therapeutics is expected to grow, from $65.1 billion in 2016 to $113 billion in 2023, at a CAGR of 8.2%.

Which products will contribute to market growth most, and which will achieve blockbuster status?

Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?

What CAGR will these companies register in the forecast period?

How many strategic consolidations have been completed in the past decade?

Which types of assets attract the largest deal values?

Reasons to buy

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.

Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.

Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.

Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.

Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.

Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.

Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.

Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.